Preparing your results

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.

Signal transducer and activator of transcription (STAT) 5b-retinoic acid receptor (RAR) alpha is the fifth fusion protein identified in acute promyelocytic leukemia (APL). Initially described in a patient with all-trans retinoic acid (ATRA)-unresponsive disease, STAT5b-RARalpha resulted from an interstitial deletion on chromosome 17. To determine the molecular mechanisms of myeloid leukemogenesis and maturation arrest in STAT5b-RARalpha(+) APL and its unresponsiveness to ATRA, we examined the effect of STAT5b-RARalpha on the activity of myeloid transcription factors including RARalpha/retinoid X receptor (RXR) alpha, STAT3, and STAT5 as well as its molecular interactions with the nuclear receptor corepressor, SMRT, and nuclear receptor coactivator, TRAM-1. STAT5b-RARalpha bound to retinoic acid response elements (RAREs) both as a homodimer and as a heterodimer with RXRalpha and inhibited wild-type RARalpha/RXRalpha transactivation. Although STAT5b-RARalpha had no effect on ligand-induced STAT5b activation, it enhanced interleukin 6-induced STAT3-dependent reporter activity, an effect shared by other APL fusion proteins including promyelocytic leukemia-RARalpha and promyelocytic leukemia zinc finger (PLZF)-RARalpha. SMRT was released from STAT5b-RARalpha/SMRT complexes by ATRA at 10(-6) M, whereas TRAM-1 became associated with STAT5b-RARalpha at 10(-7) M. The coiled-coil domain of STAT5b was required for formation of STAT5b-RARalpha homodimers, for the inhibition of RARalpha/RXRalpha transcriptional activity, and for stability of the STAT5b-RARalpha/SMRT complex. Thus, STAT5b-RARalpha contributes to myeloid maturation arrest by binding to RARE as either a homodimer or as a heterodimer with RXRalpha resulting in the recruitment of SMRT and inhibition of RARalpha/RXRalpha transcriptional activity. In addition, STAT5b-RARalpha and other APL fusion proteins may contribute to leukemogenesis by interaction with the STAT3 oncogene pathway.

Pubmed ID: 11929748


  • Dong S
  • Tweardy DJ



Publication Data

April 15, 2002

Associated Grants

  • Agency: NCI NIH HHS, Id: CA72261
  • Agency: NCI NIH HHS, Id: CA86430

Mesh Terms

  • DNA-Binding Proteins
  • Dimerization
  • Drug Interactions
  • Drug Resistance
  • Humans
  • Leukemia, Promyelocytic, Acute
  • Milk Proteins
  • Nuclear Receptor Co-Repressor 2
  • Nuclear Receptor Coactivator 3
  • Oncogene Proteins, Fusion
  • Protein Structure, Tertiary
  • Receptors, Retinoic Acid
  • Repressor Proteins
  • Response Elements
  • Retinoid X Receptors
  • STAT3 Transcription Factor
  • STAT5 Transcription Factor
  • Signal Transduction
  • Trans-Activators
  • Transcription Factors
  • Transcription, Genetic
  • Transfection
  • Tretinoin
  • Tumor Cells, Cultured